My Participation in the ERS Congress 2024
The ERS Congress 2024 in Vienna attracted close to 20,000 delegates, both onsite and online, making it a vibrant and dynamic event focused on advancing respiratory health.
ELF Networking Day at the ERS Congress
Before the official opening of the ERS Congress, I had the opportunity to participate in the ELF (European Lung Foundation) Networking Day, which set the stage for discussions on patient empowerment and the critical role of clean air in health.
Proceedings from the 7th World PH Symposium is Now Published
I am thrilled to share that the proceedings from Task Force 1 (Patient Perspective) at the 7th World Pulmonary Hypertension Symposium (WPHS) have been published in the European Respiratory Journal (ERJ).
EMA Approves WINREVAIR (Sotatercept) for Treatment of PAH
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial Hypertension (PAH).
Report from the International PHA conference
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients, and advocates from around the world, all united by a shared commitment to advancing the understanding and treatment of pulmonary
World’s 7th PH Symposium
I had the honor of representing PHA Europe at the World Symposium for Pulmonary Hypertension (PH) in Barcelona, held from June 28th until July 1st.
TORREY results in Lancet
The pharmaceutical company Gossamer Bio, celebrates a significant achievement with the publication of its TORREY Phase 2 study results in the esteemed Lancet Respiratory Medicine journal.
Report from IMPAHCT 2024
Approximately 150 pulmonary hypertension (PH) specialists convened in Barcelona in April 2024 for Ferrer’s 6th edition of the IMPAHCT meeting. Notably, Hall Skaara represented PHA Europe for the second time at the conference, serving as the sole patient advocate present.
Report from EPF’s AGM – Brussels 13th and 14 of April 2024
The European Patient Forum (EPF) recently convened its Annual General Meeting (AGM) in Brussels, inviting its full members to participate. The two-day event began with a focus on Artificial Intelligence (AI) on day one, followed by the official AGM proceedings on day two.
FDA recently approved Opsynvi
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Sotatercept approved by FDA
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the treatment of adults with pulmonary arterial hypertension (PAH).
Report from SAPH2024
The Saudi Association for Pulmonary Hypertension (SAPH) hosted its 17th annual conference in Riyadh, Saudi Arabia, from February 15 to 17, 2024. The conference featured an impressive scientific program with sessions led by numerous leading PH specialists from around the world.
Report from the PVRI congress in London – 2023
The Pulmonary Vascular Research Institute (PVRI) recently concluded its annual congress in London, England. Founded in 2006 as a charitable organization, PVRI has evolved into a global network that unites leading medical professionals worldwide with a keen interest in pulmonary hypertension and pulmonary vascular disease
15th-Year Anniversary of FCHP
The Spanish association FCHP celebrated its 15th anniversary in Madrid on December 1st. Approximately 200 guests were invited, representing a diverse group that included patients, carers, health authorities, PH researchers, PH specialists, social workers, psychologists, representatives from PHA Europe and PHA, TV celebrities, and pop